Biotechnology

Neurocrine Biosciences

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Neurocrine Biosciences Releases Expert Guidance on CRENESSITY® Treatment

Neurocrine Biosciences released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 814.5 M (forecast USD 763.79 M), actual EPS USD 1.91 (forecast USD 1.2403)

Neurosecretion Bioscience Launches Phase I Clinical Trials for Obesity Drug NBIP-2118

Neurocrine Biosciences Releases New Data on CRENESSITY®

Publication of INGREZZA®'s Impact on Patient Well-being in Journal of Clinical Psychiatry

Neurocrine Biosciences to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 771.2 M, EPS USD 1.2092

Neuro 分泌生物科学 Presents crinecerfont Phase III CAHtalyst Adult Data at AACE Annual Meeting

Neurocrine Biosciences Reports 2025 Annual Report, Emphasizing Product Growth and R&D Plans

Neurocrine Biosciences Demonstrates Higher Persistence with Ingrezza Compared to Austedo XR

Neurocrine Biosciences' Acquisition of Soleno Viewed as Fairly Valued but Market Sentiment Remains Uncertain

Neurosecretion Biotech Sciences to Pay Soleno $141.5M in Reverse Termination Fee if Deal Terminated

Neurocrine Biosciences Nears $2.5B Acquisition Deal for Soleno

Neurocrine Biosciences Q4 Earnings Miss, Sales Beat

Neurocrine Biosciences released FY2025 earnings on February 11 After-Market EST, but actual revenue and EPS are not reported.

Neurocrine Biosciences released FY2025 Q4 earnings on February 11 After-Market (EST), actual revenue USD 805.5 M (forecast USD 789.3 M), actual EPS USD 1.4782 (forecast USD 1.8087)

Neurosecret Biological Sciences Q4 Net Income Exceeds Expectations

Neurocrine Biosciences to release FY2025 Q4 earnings on February 11 After-Market EST, forecast revenue USD 790.53 M, EPS USD 1.8145

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

NBIX

Neurocrine Biosciences (NBIX) is conducting a Phase 2 clinical trial for its drug NBI-1065890 aimed at treating tardive dyskinesia. The study is randomized, double-blind, and placebo-controlled, focusing on the drug's efficacy, safety, and tolerability. As the trial progresses, it signals potential growth for NBIX in the movement disorder market, although near-term stock movements may be modest due to inherent trial risks.

Tip Ranks

Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

SLNO

ARKG

SBIO

LABU

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

nasdaq

Soleno Therapeutics

iShares Global Healthcare

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

Invesco Biotechnology & Genome ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Goldman Sachs

Nasdaq

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News

StockTitan

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News

Proshares Ultra Nasdaq Biotech

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News

In a recent report, Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurocrine (NBIX) with a price target of $188.00. Matteis, who has a 14.4% average return and a 50.51% success rate, also covers other healthcare stocks. Additionally, Canaccord Genuity's Sumant Kulkarni also issued a Buy rating for Neurocrine, while Morgan Stanley reiterated a Hold rating on the same day.

Stifel Financial

Xenon Pharma

Vertex Pharma

Ionis Pharma

Morgan Stanley

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News

04:15 PM EDT, 05/05/2026 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q1 adjusted earnings late Tuesday of $1.94 per diluted share, up from $0.70 a year earlier.Analysts polled by FactSet expected $1.73.Revenue for the three months ended March 31 was $814.5 million, up from $572.6 million a year earlier.Analysts surveyed by FactSet expected $768.3 million.The company reiterated its full-year 2026 guidance. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Factset Research

Neurocrine Biosciences Q1 Adjusted Earnings, Revenue Rise

William Blair analyst Myles Minter has maintained a Buy rating on NBIX stock, citing strong revenue performance from Crenessity and Ingrezza. He notes that Crenessity's launch is exceeding expectations and that Ingrezza has surpassed forecasts. Minter emphasizes the company's robust 2026 sales guidance and highlights upcoming catalysts, including the Soleno acquisition and the advancement of NBI-1117570 into Phase II. Needham also supports a Buy rating for the stock.

NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating

Neurocrine Biosciences(NBIX.US)

Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News

Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News

Neurocrine Biosciences Q1 Adjusted Earnings, Revenue Rise

NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating